223Ra-Dichloride Response Evaluation Using 18F-Fluciclovine PET/CT and Bone Scintigraphy in a Patient With Castration-Resistant Metastatic Prostate Cancer

被引：1
|
作者：
Wang, Jiaqiong [1 ]
Kuker, Russ [1 ]
Serafini, Aldo [1 ]
机构：
[1] Jackson Mem Hosp, Div Nucl Med, Dept Radiol, Miller Sch Med,Univ Miami Hosp, Miami, FL 33136 USA
来源：
CLINICAL NUCLEAR MEDICINE | 2020年 / 45卷 / 11期
关键词：
F-18-fluciclovine PET/CT; Ra-223-dichloride; Tc-99m-MDP; bone scan; prostate cancer; ACID; DIPHOSPHONATE; RADIUM-223; MECHANISMS; CELLS;
D O I：
10.1097/RLU.0000000000003168
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
A 66-year-old man was diagnosed with metastatic prostate cancer to the bones. The patient started(223)Ra-dichloride (Xofigo) therapy in April 2019.Tc-99m-MDP bone scan and(18)F-fluciclovine (Axumin) PET/CT showed discordant but overall complementary findings that indicated disease progression after 5 doses of Xofigo therapy. The patient's prostate-specific antigen increased from 33.81 ng/mL at baseline before Xofigo therapy and up to 394.3 ng/mL after the fifth dose of Xofigo treatment. Because of disease progression, Xofigo therapy was discontinued.
引用
收藏
页码：E486 / E488
页数：3
相关论文
共 50 条
  • [11] 223Ra-dichloride therapy in an elderly bone metastatic castration-resistant prostate cancer patient: a case report presentation and comparison with existing literature
    De Vincentis, Giuseppe
    Follacchio, Giulia Anna
    Frantellizzi, Viviana
    Prelaj, Arsela
    Farcomeni, Alessio
    Giuli, Angelo
    Bianco, Vincenzo
    Tomao, Silverio
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2018, 30 (06) : 677 - 680
  • [12] Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer
    Amorim, Barbara J.
    Prabhu, Vinay
    Marco, Sara S.
    Gervais, Debra
    Palmer, Willian E.
    Heidari, Pedram
    Vangel, Mark
    Saylor, Philip J.
    Catalano, Onofrio A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (01) : 105 - 114
  • [13] Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer
    Barbara J. Amorim
    Vinay Prabhu
    Sara S. Marco
    Debra Gervais
    Willian E. Palmer
    Pedram Heidari
    Mark Vangel
    Philip J. Saylor
    Onofrio A. Catalano
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 105 - 114
  • [14] Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer
    Gary J. R. Cook
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 16 - 17
  • [15] 223Ra-Dichloride in castration-resistant metastatic prostate cancer: improving outcomes and identifying predictors of survival in clinical practice
    Dizdarevic, Sabina
    Jessop, Maryam
    Begley, Patrick
    Main, Sean
    Robinson, Angus
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (13) : 2264 - 2273
  • [16] 223Ra-Dichloride in castration-resistant metastatic prostate cancer: improving outcomes and identifying predictors of survival in clinical practice
    Sabina Dizdarevic
    Maryam Jessop
    Patrick Begley
    Sean Main
    Angus Robinson
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 2264 - 2273
  • [17] RADIUM RA 223 DICHLORIDE IN CASTRATION-RESISTANT PROSTATE CANCER
    Joung, J. Y.
    Ha, Y-S.
    Kim, I. Y.
    DRUGS OF TODAY, 2013, 49 (08) : 483 - 490
  • [18] Prostate-Specific Antigen Flare Phenomenon During 223Ra-Dichloride Treatment for Bone Metastatic Castration-Resistant Prostate Cancer: A Case Report
    De Vincentis, Giuseppe
    Follacchio, Giulia Anna
    Frantellizzi, Viviana
    Liberatore, Mauro
    Monteleone, Francesco
    Cortesi, Enrico
    CLINICAL GENITOURINARY CANCER, 2016, 14 (05) : E529 - E533
  • [19] Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer
    Carrasquillo, Jorge A.
    O'Donoghue, Joseph A.
    Pandit-Taskar, Neeta
    Humm, John L.
    Rathkopf, Dana E.
    Slovin, Susan F.
    Williamson, Matthew J.
    Lacuna, Kristine
    Aksnes, Anne-Kirsti
    Larson, Steven M.
    Scher, Howard I.
    Morris, Michael J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (09) : 1384 - 1393
  • [20] Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer
    Jorge A. Carrasquillo
    Joseph A. O’Donoghue
    Neeta Pandit-Taskar
    John L. Humm
    Dana E. Rathkopf
    Susan F. Slovin
    Matthew J. Williamson
    Kristine Lacuna
    Anne-Kirsti Aksnes
    Steven M. Larson
    Howard I. Scher
    Michael J. Morris
    European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40 : 1384 - 1393
12345